Daewoong Pharmaceutical’s advanced biopharmaceutical manufacturing license acquired… Started CDMO business
Daewoong Pharmaceutical vs. Daewoong Pharmaceutical’s decision over the US ITC Botox lawsuit Medytox’Ajeon’
Medical newspaper mobile site, ITC final decision full text disclosed, Daewoong Pharmaceutical’s declaration of ending the strain debate
[신년사] Seung-ho Jeon, President of Daewoong Pharmaceutical, “Visualization of new drug development results this year”
Daewoong Pharmaceutical’s “‘Hoystar tablet’ could not meet the main evaluation variable in phase 2a clinical trial for corona treatment”
Daewoong Pharmaceutical’s Hoy Star tablet phase 2a main evaluation variable not satisfied…2b/3 phase progress
Daewoong Pharmaceutical confirms the treatment effect of COVID-19 in Hoystar tablet ‘2a clinical trial’
![[신년사] Seung-ho Jeon, President of Daewoong Pharmaceutical, “Visualization of new drug development results this year”](https://image.chosun.com/sitedata/image/202101/04/2021010401337_0.jpg "[신년사] Seung-ho Jeon, President of Daewoong Pharmaceutical, “Visualization of new drug development results this year”")
